Abstract：
OBJECTIVE: To investigate whether whole-body dynamic positron emission tomography (PET) is useful for differentiating benign and malignant lesions.
METHODS: In this retrospective study, data from a cohort of 146 lesions from 187 patients who consecutively underwent whole-body dynamic PET scans at our hospital for suspected lesions in the lung, lymph nodes, liver, bone, esophagus, and colon were analyzed. Patients with malignant lymphomas, accumulations > 5 cm in length along the long axis of the esophagus, or lesions in the colon in which the site of accumulation moved during the imaging period were excluded. Patients were administered 3.7 MBq/kg of fluorine-18-fluorodeoxyglucose (F-18 FDG), and dynamic imaging was initiated 60 min after administration. We defined the 60-65, 65-70, 70-75, and 75-80 min time mark as the first, second, third, and fourth pass, respectively. The static image is the summed average of all the four pass images. We measured the accumulation in the mean image of the whole-body dynamic PET scan, which was arithmetically similar to the maximum standardized uptake value (SUVmax) throughout the whole-body static images obtained during 20 min of imaging (S-SUVmax). The ratio of SUVmax in the dynamic first pass(60-65 min after FDG administration) and fourth pass(75-80 min after FDG administration) was calculated as R-SUVmax.
RESULTS: The S-SUVmax in the lung, lymph nodes, and bone did not differ significantly between the benign and malignant groups. However, there was a significant difference in R-SUVmax, which was > 1 in most malignant lesions indicating an increase in accumulation during routine scan time. Significant differences were observed between benign and malignant lesions of the liver in both S-SUVmax and R-SUVmax values, with the latter being > 1 in most malignant lesions.
CONCLUSIONS: Whole-body dynamic PET for 20 min starting 1 h after FDG administration improved the accuracy of malignant lesion detection in the liver, lymph nodes, lung, and bone. The incremental improvement was small, and the FDG dynamics in the distribution of values between benign and malignant overlapped. Additional information from whole-body dynamic imaging can help detect malignant lesions in these sites without increasing patient burden or prolonging imaging time.
METHODS: In this retrospective study, data from a cohort of 146 lesions from 187 patients who consecutively underwent whole-body dynamic PET scans at our hospital for suspected lesions in the lung, lymph nodes, liver, bone, esophagus, and colon were analyzed. Patients with malignant lymphomas, accumulations > 5 cm in length along the long axis of the esophagus, or lesions in the colon in which the site of accumulation moved during the imaging period were excluded. Patients were administered 3.7 MBq/kg of fluorine-18-fluorodeoxyglucose (F-18 FDG), and dynamic imaging was initiated 60 min after administration. We defined the 60-65, 65-70, 70-75, and 75-80 min time mark as the first, second, third, and fourth pass, respectively. The static image is the summed average of all the four pass images. We measured the accumulation in the mean image of the whole-body dynamic PET scan, which was arithmetically similar to the maximum standardized uptake value (SUVmax) throughout the whole-body static images obtained during 20 min of imaging (S-SUVmax). The ratio of SUVmax in the dynamic first pass(60-65 min after FDG administration) and fourth pass(75-80 min after FDG administration) was calculated as R-SUVmax.
RESULTS: The S-SUVmax in the lung, lymph nodes, and bone did not differ significantly between the benign and malignant groups. However, there was a significant difference in R-SUVmax, which was > 1 in most malignant lesions indicating an increase in accumulation during routine scan time. Significant differences were observed between benign and malignant lesions of the liver in both S-SUVmax and R-SUVmax values, with the latter being > 1 in most malignant lesions.
CONCLUSIONS: Whole-body dynamic PET for 20 min starting 1 h after FDG administration improved the accuracy of malignant lesion detection in the liver, lymph nodes, lung, and bone. The incremental improvement was small, and the FDG dynamics in the distribution of values between benign and malignant overlapped. Additional information from whole-body dynamic imaging can help detect malignant lesions in these sites without increasing patient burden or prolonging imaging time.
摘要：
目的：探讨全身动态正电子发射断层扫描（PET）对良恶性病变的鉴别是否有用。
方法：在这项回顾性研究中，数据来自我们医院连续接受全身动态PET扫描的187名患者的146个病变队列，淋巴结,肝脏,骨头,食道,和结肠进行了分析。恶性淋巴瘤患者，沿着食道长轴的长度>5厘米的积聚，或排除在成像期间积聚部位移动的结肠病变。患者服用3.7MBq/kg的氟-18-氟脱氧葡萄糖（F-18FDG），给药后60分钟开始动态成像。我们将60-65、65-70、70-75和75-80分钟的时间标记定义为第一个，第二,第三,第四关，分别。静态图像是所有四遍图像的总和平均值。我们测量了全身动态PET扫描的平均图像中的积累，在算术上类似于在20分钟成像期间获得的整个全身静态图像的最大标准化摄取值（SUVmax）（S-SUVmax）。将动态第一遍(FDG施用后60-65分钟)和第四遍(FDG施用后75-80分钟)中SUVmax的比率计算为R-SUVmax。
结果：肺部的S-SUVmax，淋巴结,良性和恶性组之间的骨没有显着差异。然而,R-SUVmax有显著差异，在大多数恶性病变中>1，表明在常规扫描时间内积累增加。在S-SUVmax和R-SUVmax值的肝脏良性和恶性病变之间观察到显着差异，后者在大多数恶性病变中>1。
结论：从FDG给药后1小时开始，全身动态PET20分钟可提高肝脏恶性病变检测的准确性，淋巴结,肺，还有骨头.增量改善很小，FDG动力学在良性和恶性之间的值分布重叠。来自全身动态成像的其他信息可以帮助检测这些部位的恶性病变，而不会增加患者负担或延长成像时间。
方法：在这项回顾性研究中，数据来自我们医院连续接受全身动态PET扫描的187名患者的146个病变队列，淋巴结,肝脏,骨头,食道,和结肠进行了分析。恶性淋巴瘤患者，沿着食道长轴的长度>5厘米的积聚，或排除在成像期间积聚部位移动的结肠病变。患者服用3.7MBq/kg的氟-18-氟脱氧葡萄糖（F-18FDG），给药后60分钟开始动态成像。我们将60-65、65-70、70-75和75-80分钟的时间标记定义为第一个，第二,第三,第四关，分别。静态图像是所有四遍图像的总和平均值。我们测量了全身动态PET扫描的平均图像中的积累，在算术上类似于在20分钟成像期间获得的整个全身静态图像的最大标准化摄取值（SUVmax）（S-SUVmax）。将动态第一遍(FDG施用后60-65分钟)和第四遍(FDG施用后75-80分钟)中SUVmax的比率计算为R-SUVmax。
结果：肺部的S-SUVmax，淋巴结,良性和恶性组之间的骨没有显着差异。然而,R-SUVmax有显著差异，在大多数恶性病变中>1，表明在常规扫描时间内积累增加。在S-SUVmax和R-SUVmax值的肝脏良性和恶性病变之间观察到显着差异，后者在大多数恶性病变中>1。
结论：从FDG给药后1小时开始，全身动态PET20分钟可提高肝脏恶性病变检测的准确性，淋巴结,肺，还有骨头.增量改善很小，FDG动力学在良性和恶性之间的值分布重叠。来自全身动态成像的其他信息可以帮助检测这些部位的恶性病变，而不会增加患者负担或延长成像时间。
